Anonymous
Guest
Anonymous
Guest
Here is the full announcement:
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
To: All Employees of the Johnson & Johnson Family of Companies
As part of our long-term plan to assure orderly leadership succession at Johnson & Johnson, I am pleased to announce that the Board of Directors has named Alex Gorsky as Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee, effective April 26, 2012, the date of our upcoming Annual Meeting of Shareholders. Alex was also nominated for election to the Board of Directors at the Annual Meeting.
Alex’s appointment follows a rigorous, thorough and formal multi-year succession planning process which involved the entire Board of Directors. The Board has also asked me to continue as Chairman of the Board of Directors, which I have agreed to do.
Alex has worked for Johnson & Johnson for 20 years, gaining increased and broad-based responsibilities over two separate periods of employment. Alex’s appointment to the CEO position from a role inside our company is consistent with our 126-year history. That is a testament to the quality of leaders throughout Johnson & Johnson. Information on Alex’s background and career accomplishments is attached.
As Vice Chairman of the Executive Committee, Sheri McCoy will report to Alex when he assumes the role of CEO. She will also continue to lead the Pharmaceuticals and Consumer Groups and maintain responsibility for Information Technology.
We are fortunate to have had two such strong, Credo-based leaders as Alex and Sheri for the Board to consider as internal CEO succession candidates.
Prior to April 26, the composition of the Executive Committee and current reporting relationships to Alex and me will remain intact. During this period I will work with Alex on transition to his new role and responsibilities.
Effective April 26, Alex will assume full management responsibilities for Johnson & Johnson, including chairing the Executive Committee, which I will leave at that time. In addition to Sheri, Alex’s direct reports at that time will include his current direct reports in the Medical Devices and Diagnostics groups, Global Supply Chain, Health Care Compliance & Privacy and Government Affairs & Policy; and my current direct reports in Finance, Human Resources, Law, Diversity & Inclusion and Global Corporate Affairs.
As we move into this transition, I would like to thank Sheri and Alex for their continued strong performance as Vice-Chairmen. Please join me in congratulating Alex and in committing our support to the entire Johnson & Johnson enterprise under its new executive leadership.
Bill Weldon
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
To: All Employees of the Johnson & Johnson Family of Companies
As part of our long-term plan to assure orderly leadership succession at Johnson & Johnson, I am pleased to announce that the Board of Directors has named Alex Gorsky as Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee, effective April 26, 2012, the date of our upcoming Annual Meeting of Shareholders. Alex was also nominated for election to the Board of Directors at the Annual Meeting.
Alex’s appointment follows a rigorous, thorough and formal multi-year succession planning process which involved the entire Board of Directors. The Board has also asked me to continue as Chairman of the Board of Directors, which I have agreed to do.
Alex has worked for Johnson & Johnson for 20 years, gaining increased and broad-based responsibilities over two separate periods of employment. Alex’s appointment to the CEO position from a role inside our company is consistent with our 126-year history. That is a testament to the quality of leaders throughout Johnson & Johnson. Information on Alex’s background and career accomplishments is attached.
As Vice Chairman of the Executive Committee, Sheri McCoy will report to Alex when he assumes the role of CEO. She will also continue to lead the Pharmaceuticals and Consumer Groups and maintain responsibility for Information Technology.
We are fortunate to have had two such strong, Credo-based leaders as Alex and Sheri for the Board to consider as internal CEO succession candidates.
Prior to April 26, the composition of the Executive Committee and current reporting relationships to Alex and me will remain intact. During this period I will work with Alex on transition to his new role and responsibilities.
Effective April 26, Alex will assume full management responsibilities for Johnson & Johnson, including chairing the Executive Committee, which I will leave at that time. In addition to Sheri, Alex’s direct reports at that time will include his current direct reports in the Medical Devices and Diagnostics groups, Global Supply Chain, Health Care Compliance & Privacy and Government Affairs & Policy; and my current direct reports in Finance, Human Resources, Law, Diversity & Inclusion and Global Corporate Affairs.
As we move into this transition, I would like to thank Sheri and Alex for their continued strong performance as Vice-Chairmen. Please join me in congratulating Alex and in committing our support to the entire Johnson & Johnson enterprise under its new executive leadership.
Bill Weldon
Anonymous
Guest
Anonymous
Guest
He still remains as Chairman. I don't think J&J can get back on track until he is completely gone.
Anonymous
Guest
Anonymous
Guest
Here is the full announcement:
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
To: All Employees of the Johnson & Johnson Family of Companies
As part of our long-term plan to assure orderly leadership succession at Johnson & Johnson, I am pleased to announce that the Board of Directors has named Alex Gorsky as Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee, effective April 26, 2012, the date of our upcoming Annual Meeting of Shareholders. Alex was also nominated for election to the Board of Directors at the Annual Meeting.
Alex’s appointment follows a rigorous, thorough and formal multi-year succession planning process which involved the entire Board of Directors. The Board has also asked me to continue as Chairman of the Board of Directors, which I have agreed to do.
Alex has worked for Johnson & Johnson for 20 years, gaining increased and broad-based responsibilities over two separate periods of employment. Alex’s appointment to the CEO position from a role inside our company is consistent with our 126-year history. That is a testament to the quality of leaders throughout Johnson & Johnson. Information on Alex’s background and career accomplishments is attached.
As Vice Chairman of the Executive Committee, Sheri McCoy will report to Alex when he assumes the role of CEO. She will also continue to lead the Pharmaceuticals and Consumer Groups and maintain responsibility for Information Technology.
We are fortunate to have had two such strong, Credo-based leaders as Alex and Sheri for the Board to consider as internal CEO succession candidates.
Prior to April 26, the composition of the Executive Committee and current reporting relationships to Alex and me will remain intact. During this period I will work with Alex on transition to his new role and responsibilities.
Effective April 26, Alex will assume full management responsibilities for Johnson & Johnson, including chairing the Executive Committee, which I will leave at that time. In addition to Sheri, Alex’s direct reports at that time will include his current direct reports in the Medical Devices and Diagnostics groups, Global Supply Chain, Health Care Compliance & Privacy and Government Affairs & Policy; and my current direct reports in Finance, Human Resources, Law, Diversity & Inclusion and Global Corporate Affairs.
As we move into this transition, I would like to thank Sheri and Alex for their continued strong performance as Vice-Chairmen. Please join me in congratulating Alex and in committing our support to the entire Johnson & Johnson enterprise under its new executive leadership.
Bill Weldon
A long overdue announcement, but a step in the right direction. Let's just hope all the damage to our reputation can be repaired over time under Gorsky.
Anonymous
Guest
Anonymous
Guest
Here is the full announcement:
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
To: All Employees of the Johnson & Johnson Family of Companies
As part of our long-term plan to assure orderly leadership succession at Johnson & Johnson, I am pleased to announce that the Board of Directors has named Alex Gorsky as Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee, effective April 26, 2012, the date of our upcoming Annual Meeting of Shareholders. Alex was also nominated for election to the Board of Directors at the Annual Meeting.
Alex’s appointment follows a rigorous, thorough and formal multi-year succession planning process which involved the entire Board of Directors. The Board has also asked me to continue as Chairman of the Board of Directors, which I have agreed to do.
Alex has worked for Johnson & Johnson for 20 years, gaining increased and broad-based responsibilities over two separate periods of employment. Alex’s appointment to the CEO position from a role inside our company is consistent with our 126-year history. That is a testament to the quality of leaders throughout Johnson & Johnson. Information on Alex’s background and career accomplishments is attached.
As Vice Chairman of the Executive Committee, Sheri McCoy will report to Alex when he assumes the role of CEO. She will also continue to lead the Pharmaceuticals and Consumer Groups and maintain responsibility for Information Technology.
We are fortunate to have had two such strong, Credo-based leaders as Alex and Sheri for the Board to consider as internal CEO succession candidates.
Prior to April 26, the composition of the Executive Committee and current reporting relationships to Alex and me will remain intact. During this period I will work with Alex on transition to his new role and responsibilities.
Effective April 26, Alex will assume full management responsibilities for Johnson & Johnson, including chairing the Executive Committee, which I will leave at that time. In addition to Sheri, Alex’s direct reports at that time will include his current direct reports in the Medical Devices and Diagnostics groups, Global Supply Chain, Health Care Compliance & Privacy and Government Affairs & Policy; and my current direct reports in Finance, Human Resources, Law, Diversity & Inclusion and Global Corporate Affairs.
As we move into this transition, I would like to thank Sheri and Alex for their continued strong performance as Vice-Chairmen. Please join me in congratulating Alex and in committing our support to the entire Johnson & Johnson enterprise under its new executive leadership.
Bill Weldon
Now let's hope Gorsky can put some pressure on Fasolo to clean house at the VP of HR level. This is a very unhealthy and toxic function at J&J. Time to see some of these highly incompetent and political animals hit the street so J&J can bring in some truly talented HR professionals that demonstrate courageous leadership instead of sucking up to move their career forward.
So Mr. Gorsky, will you finally use your new authority to address this issue?
Anonymous
Guest
Anonymous
Guest
Don't look for meaningful change until Weldon is really gone.
Should have brought someone in from the outside instead of picking from a list of insiders.
Succession planning usually means a puppet has been selected.
Should have brought someone in from the outside instead of picking from a list of insiders.
Succession planning usually means a puppet has been selected.
Anonymous
Guest
Anonymous
Guest
and for all his hard work, bill is getting a 55 percent increase in his bonus
http://www.pharmalot.com/2012/02/what-recalls-jj-ceo-gets-a-55-bonus-increase/
http://www.pharmalot.com/2012/02/what-recalls-jj-ceo-gets-a-55-bonus-increase/
Anonymous
Guest
Anonymous
Guest
and for all his hard work, bill is getting a 55 percent increase in his bonus
http://www.pharmalot.com/2012/02/what-recalls-jj-ceo-gets-a-55-bonus-increase/
This is shameful!